bimatoprost (Lumigan, Latisse)

Indications

• glaucoma, increased intraocular pressure
• hypotrichosis, enhancement of eyelash growth

Dosage

• 1 drop QHS

Lumigan: 0.01% or 0.03%

Pharmacokinetics

• no significant systemic accumulation
• 1/2life 45 minutes
• peak plasma time < 10 minutes
• onset of action: 4hr (IOP reduction)
• peak effect: 8-12hours
• protein binding: 88%
• volume of distribution: 0.67 L/kg
• metabolism: oxidation; N-deethylation & glucuronidation
• excretion: urine (67%); feces (25%)

Adverse effects

• common > 10%)
  • conjunctival hyperemia (25-45%)
  • growth of eyelashes (15-45%)
  • ocular pruritus (15-45%)
• uncommon 1-10%
  • xerophthalmia (3-10%)
  • visual disturbance (3-10%)
  • ocular burning (3-10%)
  • eye foreign body sensation (3-10%)
  • eye pain (3-10%)
  • pigmentation of the periocular skin (3-10%)
  • blepharitis (3-10%)
  • cataract (3-10%)
  • superficial punctate keratitis (3-10%)
  • eyelid erythema (3-10%)
  • ocular irritation (3-10%)
  • eyelash darkening (3-10%)
  • ocular discharge (1-3%)
  • tearing (1-3%)
  • photophobia (1-3%)
  • allergic conjunctivitis (1-3%)
  • asthenopia (1-3%)
  • increases in iris pigmentation (1-3%)
  • conjunctival edema (1-3%)
• other
  • blurred vision
  • may permanently darken iris, eyelashes & eyelids

Mechanism of action

• prostaglandin analog
• increases ouflow of aqueous humor

Notes

Manufacturer: Allergan

More general terms

• prostaglandin analog; prostanoid

Database

• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5311027
• PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=127909